The Centers for Disease Control and Prevention (CDC) on Monday warned that a deadly fungus called Candida auris (C. auris) is spreading at an "alarming rate" in the U.S. healthcare facilities. 

“The rapid rise and geographic spread of cases is concerning and emphasizes the need for continued surveillance, expanded lab capacity, quicker diagnostic tests, and adherence to proven infection prevention and control,” said CDC epidemiologist Dr. Meghan Lyman, lead author of the paper, in a press release. 

Adding to the agency's concerns, the number of infections that were resistant to echinocandins, which is the antifungal medicine most commonly used to treat C. auris infections, tripled in 2021. 

The CDC classified C. auris as an "urgent antimicrobial resistance (AR) threat," meaning "it is often resistant to multiple antifungal drugs, spreads easily in healthcare facilities, and can cause severe infections with high death rates."

Between 2016, when C. auris was first reported, and 2021, there have been a total of 3,270 clinical cases reported and 7,413 screening cases. 

The agency said "poor general infection prevention and control (IPC) practices in healthcare facilities" are responsible for the spread. However, expanded efforts to detect cases is also responsible for the jump in reported cases.

Share:
More In Science
FDA Panel Recommends Pfizer Vaccine for Kids Ages 5-11
An FDA panel has recommended the low-dose Pfizer vaccine for kids ages five to 11. The recommendation now cues up the FDA to authorize the vaccine. Next week, the CDC will consider its own authorization. Once signed off by the CDC, the Pfizer vaccine can be administered in children immediately. Dr. Christina Johns, Senior Medical Advisor at PM Pediatrics, joined Cheddar's Search for a Cure.
A Look Ahead at G20 Summit and COP26 on Addressing the Climate Crisis
World leaders will converge this weekend at the 2021 G20 Summit in Rome and the UN COP26 conference in Glasgow with the climate crisis on the agenda. Lord Adair Turner, chair of the Energy Transitions Commission, joined Cheddar to discuss what people can expect to come out of the climate-focused conferences. Turner also noted that one of the biggest hurdles for the attending nations will be coming to a uniform decision on expanding on the Paris Climate Accord goals that have become insufficient to prevent global warming by 1.5 degrees celsius.
Expanding Genetic Testing for Women Everywhere
Nicole Lambert, President at Myriad Genetics joins ChedHER to discuss how to expand access to genetic testing for all women, and how her experience as a 'pre-vivor' motivates her role in the industry.
Proptech Startup Juno Raises $20 Million
Proptech startup Juno recently raised $20 million in a Series A funding round. The company says the funds will be used to further its mission of building sustainable and affordable apartment buildings across the United States. Juno Co-Founder and CEO Jonathan Sherr joined Cheddar News' Closing Bell to discuss.
Innovation in Breast Cancer Screening
Stacey Stevens, President of iCAD, joins 'Cheddar Innovates' to discuss how 'Profound A.I. Risk' works as a short-term breast cancer risk estimation for women.
Merck to Offer Poorer Countries COVID-19 Pill Formula for Free
Pharmaceutical company Merck has announced that it will share the formula of its COVID-19 pill with poor countries free of charge. The company still intends to charge wealthier nations leaving the end cost at more than $700 per five-day treatment course.
Deal or No Deal, ISIS Threat & Memecoin Insanity
Dems race for a deal on President Biden's economic agenda ahead of his big foreign trip. What to make of the latest threat assessment in Afghanistan. Plus, the meme cryptocurrency of the moment that's now worth more than many Fortune 500 companies.
Load More